Showing results (31-40 of 94) with videos related to
Sort By:
Pageof 10
Surgical Oncology Clinics of North America|October 6, 1997
Adjuvant and neoadjuvant chemotherapy for urothelial carcinomaJ A McCaffrey, H W HerrSeminars in Oncology|December 1, 1992
Ifosfamide-based chemotherapy for patients with resistant germ cell tumors: the Memorial Sloan-Kettering Cancer Center experienceR J Motzer, D F Bajorin, V Vlamis, et al.Investigational New Drugs|February 1, 1991
Phase II trial of cisplatin and etoposide in patients with metastatic melanomaO Eton, D F Bajorin, P B Chapman, et al.Investigational New Drugs|January 1, 1995
Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumorsH S Puc, D F Bajorin, G J Bosl, et al.Irish Journal of Medical Science|November 1, 2006
Collecting duct carcinoma of the kidney: a case report with variable immunohistochemistryR M Connolly, P Downey, J A McCaffreyJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1997
High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumorsR J Motzer, M Mazumdar, D F Bajorin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicityR J Motzer, M Mazumdar, G J Bosl, et al.Cancer Research|November 1, 1986
Pharmacokinetics of cis-diamminedichloroplatinum(II) after administration in hypertonic salineD F Bajorin, G J Bosl, N W Alcock, et al.The Journal of Urology|February 26, 1999
Can p53 help select patients with invasive bladder cancer for bladder preservation?H W Herr, D F Bajorin, H I Scher, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2001
Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapyM Mazumdar, D F Bajorin, J Bacik, et al.Pageof 10